Omburtamab I-131 clinical trials
How each study uses omburtamab I-131 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- 131I-omburtamab
- 2
Studies by the year they started
4 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Y-mAbs Therapeutics (3) · Memorial Sloan Kettering Cancer Center (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test omburtamab I-131.
- Jul 2027A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the PeritoneumPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses omburtamab I-131 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the PeritoneumActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04022213Written as 131 I-omburtamab
- 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesTerminatedPhase 2/3Y-mAbs TherapeuticsNCT03275402Written as 131I-omburtamab
- Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal CancerTerminatedPhase 1Y-mAbs TherapeuticsNCT00089245Written as Iodine I 131 MOAB 8H9
- 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine GliomaWithdrawnPhase 1Y-mAbs TherapeuticsNCT05063357Written as 131I-Omburtamab
Given beside what is tested · 1 — omburtamab I-131 is usual care or a partner of the new treatment
Codes
What other systems call omburtamab I-131 · ClinicalTrials.gg INT001146
- MeSH (NLM) C000633765omburtamab I-131Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) B6PMV8U3C4OMBURTAMAB I-131Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633765 | omburtamab I-131 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | B6PMV8U3C4 | OMBURTAMAB I-131 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.